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Abstract
OBJECTIVE: To observe effect of Liuweibuqi Cap-
sule, a Traditional Chinese Medicine (TCM), on the
janus kinase (JAK)/signal transducer and activator
of transcription (STAT) pathway and matrix metallo-
proteinases (MMPs) in a chronic obstructive pulmo-
nary disease (COPD) rat model with lung deficiency
in terms of TCM's pattern differentiation.
METHODS: Rats were randomly divided into a nor-
mal group, model group, Liuweibuqi group, Jinshui-
bao group, and spleen aminopeptidase group (n=
10). Aside from the normal group, all rats were ex-
posed to smoke plus lipopolysaccharide tracheal in-
stillation to establish the COPD model with lung de-
ficiency. Models were established after 28 days and
then the normal and model groups were given nor-
mal saline (0.09 g/kg), Liuweibuqi group was given
Liuweibuqi capsule (0.35 g/kg), Jinshuibao group
was given Jinshuibao capsules (0.495 g/kg), and
the spleen group was given spleen aminopepti-
dase (0.33 mg/kg), once a day for 30 days. Changes
in symptoms, signs, and lung histology were ob-
served. Lung function was measured with a spirom-
eter. Serum cytokines were detected using en-
zyme-linked immunosorbent assay, and changes in
the JAK/STAT pathway, MMP-9, and MMPs inhibitor
1 (TIMP1) were detected by immunohistochemis-
try, RT-PCR, and western blotting, respectively.
RESULTS: Compared with the normal group, lung
tissue was damaged, and lung function was re-
duced in the model control group. Additionally, the
levels of interleukin (IL)-1β, γ interferon (IFN-γ), and
IL-6 were higher, while IL-4 and IL-10 were lower in
the model control group than those in the normal
group. The expressions of JAK1, STAT3, p-STAT3,
and MMP-9 mRNA and protein in lung tissue were
higher, and TIMP1 mRNA and protein was lower in
the model group compared with the normal group.
After treatment, compared with the model group,
the expression of inflammatory cytokines was low-
er in each treatment group, and expressions of JAK/
STAT pathway, MMPs were lower. Compared with
the positive control groups, the Jinshuibao and
spleen aminopeptidase groups, lung function was
better, and JAK1, STAT3, and p-STAT3 protein were
lower and TIMP1 was higher in the Liuweibuqi
group.
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CONCLUSION: Liuweibuqi capsules can improve
the symptoms of COPD possibly by regulating the
expression of the JAK1/STAT3 pathway and MMP9/
TIMP1.
© 2015 JTCM. All rights reserved.
Key words: Pulmonary disease, chronic obstruc-
tive; Lung deficiency; Liuweibuqi capsules; Janus ki-
nases; STAT Transcription Factors; Matrix metallo-
proteinases
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a re-
spiratory condition that manifests as central airway mu-
cus hypersecretion, and peripheral airway reconstruc-
tion and scar tissue formation.1 The pathogenesis of
COPD is complex, but the JAK/STAT signaling path-
way and protease/anti-protease systems play an impor-
tant role.2,3 COPD is also associated with matrix metal-
loproteinases (MMPs), and tissue inhibitor of metallo-
proteinase (TIMPs). Studies have shown that the Janus
kinase (JAK)/signal transducer and activator of tran-
scription (STAT) signaling pathway can lead to the ac-
cumulation of a large number of proinflammatory cyto-
kines, and increase the inflammatory response.4 The di-
rect result of airway injury is lung tissue damage,
which causes coughing, wheezing, and reduced lung
function. MMP and TIMP expression imbalance
causes degradation of extracellular matrix deposition
disorder, which results in airway damage and emphyse-
ma. This study investigated the expression and relation-
ship between the JAK/STAT signaling pathway and
MMPs/TIMPs in a rat model of COPD. Preclinical
findings show that Liuweibuqi capsules can not only re-
duce airway inflammation in patients with COPD, but
also significantly improve cough, wheezing, shortness
of breath, fatigue, and improve lung function in pa-
tients with COPD.5,6 In this study, a rat COPD model
was established by administration of lipopolysaccharide
and smoke. Liuweibuqi capsules were administered af-
ter model establishment and lung function and lung
tissue morphological changes, and changes in the
STAT pathway and MMP system were observed.
MATERIALS ANDMETHODS
Experimental animals
Fifty male Sprague-Dawley (SD) rats (180-200 g) were
purchased from the Experimental Animal Center of
Anhui Province (Hefei, China). All animals were
housed in specific pathogen free (SPF) conditions, and
given access to water and food ad libitum. The study
protocol was approved by the Ethics Committee of An-
hui University of Chinese Medicine.
Model establishment and grouping
Rats were randomly divided into five groups by ran-
dom number table method, with 10 rats in each: nor-
mal control (NC) group, model control (MC) group,
Liuweibuqi group (LWBQ), Jinshuibao group (JSB),
and spleen aminopeptidase group (PAT). Apart from
the NC group, all rats were anesthetized with 10%
chloral hydrate and their tracheas exposed to 200 μL
of 1 mg/mL lipopolysaccharide (LPS, Sigma, St. Louis,
MO, USA, No. 20110314574). The rats were placed
in a chamber with smoke from ignition of a 50 g saw-
dust and 0.682 g cigarette tobacco mixture (Chuzhou,
China, tar 13.5 mg/g, nicotine 0.48 mg/g). The rats
were exposed to the smoke for 30 min per day for 28
days to establish the rat models.7 The Qi deficiency
models were established by changing smoking for three
times per day in the first 22 days.8 COPD model crite-
ria were based on lung function and pathological
changes of lung tissue. The Qi deficiency model crite-
ria were based on biological signs of change, including
activity, hair, body weight, food intake, and coughing.
Treatment administration
Treatments started from day 28. The NC and MC
groups were given 0.9% (physiological) saline (10 mL/
kg). The LWBQ, JSB, and PAT groups were respective-
ly given Liuweibuqi capsules (0.35 g/kg), Jinshuibao
capsules (0.495 g/kg), and spleen aminopeptidase
(0.33 mg/kg) for 30 days.
Medicine and reagents
Liuweibuqi Capsules were from Anhui Medical Univer-
sity First Affiliated Hospital Pharmacy Center, batch
number: 2011070501 (Hefei, China). Jinshuibao Cap-
sules were from Jiangxi Jinshuibao pharmaceutical com-
pany (Jiangxi, China). Spleen aminopeptidase was
from Dalian Baili pharmaceutical manufacturing (Da-
lian, China). LPS was from Sigma; cigarettes were
from Chuzhou Cigarette Factory (Chuzhou, China);
IFN (interferon)-γ, IL (interleukin)-4, IL-6, and IL-10
detection kits were purchased from R&D Systems (Em-
eryville, CA, USA); JAK1, p-JAK1, STAT3, p-STAT3,
MMP9, and TIMP1 antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Observation of rats
Rat body weight, activity, reaction time, fur and feces,
death rate, respiratory rate, coughing, respiratory secre-
tions, sputum, and other COPD symptoms and signs
were monitored.
Evaluation of pulmonary function
Pulmonary function was observed by forced vital capac-
ity (FVC) and average expiratory flow, which was calcu-
lated by dividing FVC by the value for forced expirato-
ry flow in 0.3 s (FEV0.3) and multiplying by 100%. Ad-
ditionally, peak expiratory flow (PEF) was assessed.
These measurements were obtained using the pulmo-
nary function test apparatus for small animals 30 days
after administration.
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Rat lung tissue morphology
Lung tissues were fixed in 10% formalin after 48 h.
The right upper lobe and hilar organizations were rou-
tinely washing, dehydrated, embedded in paraffin, and
cut into 5 μm serial sections. The sections were then
dewaxed, dehydrated, stained with HE, and observed
with light microscopy (Olympus Inc., Tokyo, Japan).
Bronchus and lung tissue were analyzed for morpholog-
ical changes (Jetta Company, Shanghai, China).
Detection of IFN-γ, IL-4, IL-6, and IL-10 in serum
using enzyme linked immunosorbent assay(ELISA)
Detection was performed in accordance with the in-
structions of ELISA kit manufacturer (R&D Systems,
Emeryville, CA, USA). In brief, the primary antibody
was (interferon-γ, interleukin-4, interleukin-6, and in-
terleukin-10) diluted (1-10 μg/mL) in coating solu-
tion. Then, 100 µL diluted antibody was added to ap-
propriate wells, and incubated for 2 h at room tempera-
ture. The plate was emptied, residual liquid removed,
and washed twice with 300 µL 0.05% Tween-20.
Then, 300 µL blocking solution was added to each
well and incubated for 1 h at room temperature. Then,
the plate was washed twice with 300 µL wash solution.
Next, 100 µL of diluted biotinylated detection anti-
body was added to each well and incubated for 1 h at
37 ℃ , then the plate was washed three times. Then,
100 µL diluted AKP conjugated streptavidin was add-
ed to each well and incubated for 1 h at room tempera-
ture. The plate was emptied and washed three times for
5 min each. The plate was then washed five more
times. Then, 200 µL of substrate was placed into each
well and the color developed for 30 min at room tem-
perature. Finally, 0.05 mL 2 M of H2SO4 was added to
each well, and immediately read with a plate reader at
405-410 nm.
Immunohistochemical detection of lung tissue
MMP-9, TIMP1, JAK1, STAT3
Immunohistochemical staining of MMP-9, TIMP1,
JAK1, and STAT3 in lung tissue was detected by the
streptavidin-perosidase (SP) method according to the
manufacturer's instructions. The negative control used
phosphate buffered saline (PBS) instead of an anti-car-
ry. Positive staining was indicated by brown particles.
Five high-power fields were randomly selected on each
section for analysis by an image analysis system. Immu-
noreactive cells were analyzed, and the average optical
density was measured.
Detection of MMP-9, TIMP1, JAK1, STAT3 mRNA
in lung tissue by RT-PCR
Total RNA of lung tissue was extracted using TRIzol
(Invitrogen, Diego, CA, USA, No. 1259673). Re-
verse transcriptase was from Invitrogen (Diego, CA,
USA, No. 696045), thermal cycler was from Biome-
tra (Goettingen, Germany, model: T1-Thermob-
lock), electrophoresis apparatus was from Bio-Rad
(Hercules, CA, USA, model: Power PAC 300), and
the gel image analysis instrument was from
Bio-Rad (Hercules, CA, USA, model: Gel Doc
XR). Band brightness of MMP-9, TIMP1, JAK1,
STAT3 changes were observed, and the optical den-
sity of each band was analyzed. The levels of
MMP-9, TIMP1, JAK1, and STAT3 are given rela-
tive to glyceraldehyde-3-phosphate Dehydrogease
(GAPDH) levels as control.
Detection of JAK1/STAT3 pathway, MMP-9,
TIMP1 protein of lung tissue by western blot analysis
Protein samples of lung tissue were prepared and sub-
jected to protein gel electrophoresis (Bio-Rad). The gel
was transferred to a membrane, blocked, and incubat-
ed with a primary antibody: the JAK1 (Santa-Cruz,
CA, USA, sc-376996), p-JAK1 (Santa-Cruz, CA,
USA, sc-377043), STAT3 (Santa-Cruz, CA, USA,
sc-482), p-STAT3 (Santa-Cruz, CA, USA, sc-8001-R),
MMP-9 (Santa-Cruz, CA, USA, sc-21733), or TIMP1
(Santa-Cruz, CA, USA, sc-21734) diluted 1 : 1000.
The diluted primary antibody was incubated at room
temperature for 1-2 h. Secondary antibody was incu-
bated for 30-60 min. Membranes were visualized with
enhanced chemiluminescence. Software was used for
analysis and processing of protein bands. The relative
density of each band in each group was calculated to
beta-actin as the control.
Statistical analysis
Continuous variables are the mean±standard deviation
( xˉ ± s). All samples were tested to ascertain if they fol-
lowed a normal distribution. Data comparison among
groups was performed using analysis of variance. Com-
parison between groups were tested by One-Way analy-
sis of variance and least significant difference test. SPSS
Version 17.0 (SPSS Inc., Chicago, IL, USA) was used
for data analyses. P < 0.05 was considered significant.
RESULTS
Biological observation
In the NC group, the food intake and body weight
gradually increased. Rat respiratory rate was steady,
there were no respiratory secretions, and no smell or
sputum. The MC rats showed edge off appetite, brown
hair and shedding. Rat body weight was less than that
of the NC group (P < 0.05, Table 1). The MC group
had shortness of breath, and the respiratory rate of the
MC group (2.12 ± 0.69) was significantly higher than
that of the NC group (1.42 ± 0.39). Additionally, respi-
ratory secretions spilled over from the nose and mouth
in the MC group. There were symptoms of cough and
airway sputum, indicating that the MC group had low-
er lung function, and decreased exercise tolerance.
These are the characteristics of Qi deficiency in TCM.
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After treatment, the symptoms of rats were better in
comparison with the MC group. Body weight and re-
spiratory frequency were significantly better than that
in the MC group, and the LWBQ group was better than
those in the other treatment groups (P< 0.05,Table 1).
Changes in lung function
Compared with the NC group, lung function parame-
ters such as FEV0.3, FVC, FEV0.3/FVC were lower in
the MC rats (P < 0.05). Compared with the MC
group, FEV0.3, FVC, and FEV0.3/FVC were higher in
the treatment group (P < 0.05). Compared with the
LWBQ group, FEV0.3, FEV0.3/FVC, and PEF were low-
er in the PAT group (P < 0.05, Table 2).
Morphological changes in lung tissue
In the NC group there were tracheal mucociliary regu-
lar columnar epithelial cells, the cilia were arranged in
neat rows, trachea and bronchi were seen at all levels of
goblet cells, and there was no gland hyperplasia or in-
flammatory cell infiltration (Figure 1A). In the MC
group, there was tracheal epithelial shedding, goblet
cell and glandular hypertrophy, and there was wall and
inflammatory cell infiltration. Additionally, the bron-
chial mucosal folds increased in variable length, there
were many neutrophils in small endobronchial tissue,
there were narrow distal terminal bronchioles, the respi-
ratory bronchioles and alveolar ducts had cystic dilata-
tion, alveolar enlargement, bubble wall thinning, and
there was centrilobular emphysema. Some alveolar ex-
pansion was observed to be alveolar emphysema (Fig-
ure 1B). In the LWBQ group, there was little inflam-
matory cell infiltration, less destruction of alveolar sep-
ta, less tracheal mucociliary damage, and more com-
plete columnar epithelial cells. The cilia were also ar-
ranged in a more structured pattern (Figure 1C). The
JSB group (Figure 1D) and PAT group (Figure 1E)
had moderate infiltration of inflammatory cells in the
bronchial alveolar lumen, epithelial necrosis, fewer cil-
ia, and some alveolar expansion into vesicles of varying
sizes.
Changes in serum cytokines
Compared with the NC group, the expression of IL-4
and IL-10 was lower, and IFN-γ and IL-6 expression
was higher in the MC group (P < 0.05). Compared
with the MC group, IL-4 and IL -10 expression were
elevated, while IFN-γ and IL-6 were lower in the LW-
Group
NC
MC
LWBQ
JSB
PAT
Body weight (g)
76.6±16.6
51.2±15.5a
63.2±14.9b
55.6±14.4c
57.8±12.7
Respiratory rate (Hz)
1.4±0.4
2.1±0.3d
1.6±0.4b
1.7±0.5
1.9±0.4c
Notes: the normal and model groups were given normal saline
(0.09 g/kg); Liuweibuqi group was given Liuweibuqi capsule
(0.35 g/kg); Jinshuibao group was given Jinshuibao capsules
(0.495 g/kg), and the Spleen group was given spleen aminopepti-
dase (0.33 mg/kg), once a day for 30 days. NC: normal control;
MC: model control; LWBQ: Liuweibuqi capsule; JSB: Jinshui-
bao capsule; PAT: spleen aminopeptidase. Compared with NC
group, aP < 0.01, dP < 0.05; compared with MC group, bP <
0.05; compared withLWBQ group, cP < 0.05.
Table 1 Comparison of body weight and respiratory frequen-
cy in rats (n = 10, xˉ ± s)
Group
NC
MC
LWBQ
JSB
PAT
FEV0.3 (mL)
6.0±1.5
4.9±1.1a
6.0±1.0b
5.2±1.0
4.6±0.9c
FVC (mL)
7.7±1.9
5.5±2.0d
7.1±2.2b
6.9±1.8b
6.9±1.7b
FEV0.3/FVC (%)
93.8±2.7
80.4±2.8d
92.9±3.0e
91.4±2.8e
88.9±2.3bc
PEF (mL/s)
42.6±6.8
34.8±7.2d
29.5±4.9e
40.3±4.5e
35.8±8.6c
Notes: the normal and model groups were given normal saline (0.09 g/kg); Liuweibuqi group was given Liuweibuqi capsule (0.35 g/kg);
Jinshuibao group was given Jinshuibao capsules (0.495 g/kg), and the Spleen group was given spleen aminopeptidase (0.33 mg/kg), once
a day for 30 days. NC: normal control; MC: model control; LWBQ: Liuweibuqi capsule; JSB: Jinshuibao capsule; PAT: spleen aminopep-
tidase; FEV0.3: forced expiratory flow in 0.3 s; FVC: forced vital capacity; PEF: peak expiratory flow. Compared with NC group, aP < 0.05,
dP < 0.01; compared with MC group, bP < 0.05, eP < 0.01; compared with LWBQ group, cP < 0.05.
Table 2 Comparison of lung function parameters in rats (n = 10, xˉ ± s)
A B C D E
Figure 1 The morphological changes in lung tissue (HE, ×200)
A: NC group; B: MC group; C: LWBQ group; D: JSB group; E: PAT group. The normal and model groups were given normal saline
(0.09 g/kg); Liuweibuqi group was given Liuweibuqi capsule (0.35 g/kg); Jinshuibao group was given Jinshuibao capsules (0.495
g/kg), and the Spleen group was given spleen aminopeptidase (0.33 mg/kg), once a day for 30 days. NC: normal control; MC: mod-
el control; LWBQ: Liuweibuqi capsule; JSB: Jinshuibao capsule; PAT: spleen aminopeptidase; HE: hematoxylin and eosin.
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BQ group (P < 0.05). Compared with the LWBQ
group, IL-6 expression was higher in the PAT group,
and IL-6 and IFN-γ expression was higher in the JSB
group (P < 0.05, Figure 2).
Comparison of MMP-9, TIMP1, JAK1, and STAT3
optical density value in lung tissue
Compared with the NC group, MMP-9, JAK1, and
STAT3 optical density values of lung tissue were high-
er, while TIMP1 optical density values were lower in
the MC group. MMP-9, JAK1, and STAT3 average op-
tical density values in the LWBQ group were lower,
and TIMP1 optical density was higher than that in the
MC group. Compared with LWBQ, JAK1, and
STAT3 optical density values were higher in the JSB
group. MMP-9 optical density value was higher, and
TIMP1 lower in the PAT group compared with the
LWBQ (Figure 3).
Figure 2 Expression of serum IFN-γ, IL-4, IL-6, and IL-10 in rats
The normal and model groups were given normal saline (0.09 g/kg); Liuweibuqi group was given Liuweibuqi capsule (0.35 g/kg);
Jinshuibao group was given Jinshuibao capsules (0.495 g/kg), and the Spleen group was given spleen aminopeptidase (0.33 mg/
kg), once a day for 30 days. NC: normal control group; MC: model control group; LWBQ: Liuweibuqi capsule group; JSB: Jinshuibao
capsule group; PAT: spleen aminopeptidase group; IFN-γ: interferon-γ; IL: interleukin. Compared with NC group, aP < 0.01, eP <
0.05; compared with MC group, dP < 0.05, bP < 0.01; compared with LWBQ group, cP < 0.05.
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Figure 3 Comparison of optical density values for MMP-9, TIMP1, JAK1, and STAT3 in lung tissue
A: MMP9, B: TIMP1, C: JAK1, D: STAT3. The normal and model groups were given normal saline (0.09 g/kg); Liuweibuqi group was
given Liuweibuqi capsule (0.35 g/kg); Jinshuibao group was given Jinshuibao capsules (0.495 g/kg), and the Spleen group was
given spleen aminopeptidase (0.33 mg/kg), once a day for 30 days. MMP: matrix metalloproteinase; TIMP: tissue inhibitor of ma-
trix metalloproteinase; JAK: janus kinase; STAT: signal transducer and activator of transcription; NC: normal control; MC: model
control; LWBQ: Liuweibuqi capsule; JSB: Jinshuibao capsule; PAT: spleen aminopeptidase.
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Expression of JAK1/STAT3 signaling pathway,
MMP-9, TIMP1 gene and protein in lung tissue
RT-PCR and western blot results showed that com-
pared with the NC group, JAK1, STAT3, and MMP-9
mRNA expression in lung tissue were higher (P<0.05,
Table 3, Figure 4), and the expression of MMP-9,
JAK1, p-JAK1, STAT3, and p-STAT3 protein were
higher (P < 0.05, Table 4, Figure 5), but TIMP1
mRNA and protein expression were lower in the MC
group (P < 0.05, Table 3, 4; Figures 4, 5). Compared
with the MC group, JAK1 and MMP-9 mRNA expres-
sion and JAK1, p-JAK1, MMP-9, and p-STAT3 pro-
tein expression were lower, but TIMP1 mRNA and
protein expression were higher in the LWBQ group
(P < 0.05, Table 3, 4; Figure 4, 5). Compared with the
LWBQ group, MMP-9 mRNA and JAK1, p-JAK1,
and MMP-9 protein were higher, but TIMP1 protein
was lower in the JSB group (P < 0.05, Table 3, 4; Fig-
ure 4, 5). JAK1 mRNA and JAK1, p-STAT3, and
MMP-9 protein were higher, while TIMP1 protein
was lower in the PAT group compared with the LWBQ
group (P < 0.05, Table 3, 4; Figure 4, 5).
Correlation analysis
JAK1 mRNA, STAT3 protein were positively correlat-
ed with IL-6. MMP-9 mRNA was negatively correlat-
ed with FEV0.3 and IL-10. p-STAT3 protein was posi-
tively correlated with IFN-γ. TIMP1 protein was posi-
tively correlated with PEF. STAT3 protein was nega-
tively correlated with FEV0.3. MMP-9 protein was nega-
tively correlated with PEF (P < 0.05). JAK1, STAT3,
and MMP-9 were positively correlated with p-STAT3.
STAT3 was positively correlated with p-JAK1. MMP-9
was negatively correlated with TIMP1 (P < 0.05, Ta-
bles 5, 6).
DISCUSSION
This study created an intratracheal instillation of lipo-
polysaccharide COPD model. This model can simulate
the COPD clinical pathology of airway inflammatory
cell infiltration resulting in mucus hypersecretion. The
model also induces TCM Qi deficiency by passive
smoking, which causes airway remodeling, emphyse-
ma, and other structural changes. The results showed
that shortness of breath and respiratory frequency sig-
nificantly accelerated the outflow of respiratory secre-
tions. Moreover, cough and airway sputum could be
heard in the model rats. Therefore, this model is consis-
tent with COPD and lung deficiency clinical patholog-
ical features.
Modeled rats with COPD have airway infiltration of
inflammatory cells, pathological changes in lung tissue,
decreased pulmonary function. LPS can directly or in-
directly stimulate lung macrophages and neutrophils,
thereby inducing JAK1 phosphorylation in the JAK1/
Group
NC
MC
LWBQ
JSB
PAT
MMP-9
0.69±0.16
1.34±0.26a
0.92±0.17b
1.14±0.24c
0.93±0.20b
TIMP1
1.40±0.21
0.59±0.17a
1.15±0.22b
0.92±0.21d
0.79±0.23d
JAK1
0.36±0.08
0.68±0.15a
0.47±0.12b
0.55±0.10d
0.59±0.08c
STAT3
0.42±0.09
0.57±0.17e
0.47±0.15
0.51±0.09
0.53±0.11
Notes: the normal and model groups were given normal saline (0.09 g/kg); Liuweibuqi group was given Liuweibuqi capsule (0.35 g/kg);
Jinshuibao group was given Jinshuibao capsules (0.495 g/kg), and the Spleen group was given spleen aminopeptidase (0.33 mg/kg), once a
day for 30 days. NC: normal control; MC: model control; LWBQ: Liuweibuqi capsule; JSB: Jinshuibao capsule; PAT: spleen aminopepti-
dase; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of matrix metalloproteinase; JAK: janus kinase; STAT: signal transducer and
activator of transcription. Compared with NC group aP < 0.01, eP < 0.05; compared with MC group dP < 0.05, bP < 0.01; compared with
LWBQ group, cP < 0.05.
Table 3 Comparison of MMP-9, TIMP1, JAK1, and STAT3 mRNA in lung tissue (n = 10, xˉ ± s)
Group
NC
MC
LWBQ
JSB
PAT
JAK1
0.85±0.12
1.02±0.21a
0.64±0.15b
0.89±0.17bd
0.86±0.16c
p-JAK1
0.51±0.09
0.97±0.17e
0.48±0.05b
0.79±0.11cf
0.49±0.08f
STAT3
0.68±0.18
0.93±0.17e
0.85±0.19
0.82±0.15
0.81±0.15
p-STAT3
0.55±0.06
0.79±0.14e
0.51±0.12
0.58±0.13
0.64±0.19c
MMP-9
0.78±0.11
1.26±0.27e
0.85±0.18b
0.98±0.21cf
1.02±0.23cf
TIMP1
0.98±0.18
0.66±0.14e
0.85±0.12b
0.71±0.15c
0.72±0.13cf
Table 4 Comparison of MMP-9, TIMP1, JAK1, and STAT3 protein in lung tissue (n = 10, xˉ ± s)
Notes: the normal and model groups were given normal saline (0.09 g/kg); Liuweibuqi group was given Liuweibuqi capsule (0.35 g/kg);
Jinshuibao group was given Jinshuibao capsules (0.495 g/kg), and the Spleen group was given spleen aminopeptidase (0.33 mg/kg), once a
day for 30 days. NC: normal control; MC: model control; LWBQ: Liuweibuqi capsule; JSB: Jinshuibao capsule; PAT: spleen aminopepti-
dase; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of matrix metalloproteinase; JAK: janus kinase; STAT: signal transducer and
activator of transcription. Compared with NC group, aP < 0.05, eP < 0.01; compared with MC group, cP < 0.05, bP < 0.01; compared with
LWBQ group, cP < 0.05, dP < 0.01.
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STAT3 signaling pathway. JAK1 activation can rapidly
activate STAT3 phosphorylation. Activation of the
JAK1/STAT3 pathway was involved in cell prolifera-
tion, differentiation, and apoptosis. The STAT path-
way transduction process occurs via cytokine receptors
on the cell membrane in which liganded receptors di-
merize causing a complex aggregation of receptors.
JAK1 becomes phosphorylated, and then STAT3 be-
comes phosphorylated. p-STAT moves to the nucleus
and interacts with other transcription factors to regu-
late gene transcription.9,10 p-STAT3 can also contribute
to increased inflammatory response, thereby increasing
the severity of COPD. IL-6 is a major regulator of
JAK1/STAT3 activation in COPD lung epithelial and
endothelial cells. IL-6 can activate STAT3 directly, and
is accompanied by the activation of STAT3.
Study has shown that expression of MMP-9 is higher,
and TIMP-1 levels are lower in COPD patients. We
found that MMP-9 and inflammatory cytokines are
positively correlated. Further correlation analysis
showed that JAK1, STAT3, and MMP-9 were positive-
ly correlated with p-STAT3, and STAT3 was positively
correlated with p-JAK1, while MMP-9 was negatively
Index
mRNA
Protein
p-JAK1
JAK1
STAT3
MMP-9
TIMP1
JAK1
STAT3
p-STAT3
MMP-9
TIMP1
FVC
﹣0.145
﹣0.095
0.245
﹣0.154
﹣0.117
0.074
﹣0.296
﹣0.135
0.108
FEV0.3
﹣0.095
﹣0.114
﹣0.476a
﹣0.405
﹣0.096
﹣0.475a
﹣0.024
﹣0.093
0.186
PEF
﹣0.089
﹣0.047
﹣0.217
0.174
0.106
﹣0.095
0.283
﹣0.494a
0.468a
IFN-γ
﹣0.001
﹣0.078
﹣0.085
﹣0.142
0.064
﹣0.026
0.515b
﹣0.213
0.017
IL-4
﹣0.283
﹣0.463a
﹣0.221
﹣0.164
﹣0.066
﹣0.206
﹣0.165
﹣0.045
0.024
IL-6
0.479a
﹣0.067
﹣0.064
﹣0.065
﹣0.201
0.454a
0.266
﹣0.042
0.307
IL-10
0.074
﹣0.265
﹣0.486a
﹣0.145
﹣0.391
0.067
﹣0.195
﹣0.309
0.305
Table 5 Relationships between the JAK1/STAT3 pathway, MMP-9, and TIMP1 in COPD (r value)
Notes: r is relevance coefficient. MMP: matrix metalloproteinase; TIMP: tissue inhibitor of matrix metalloproteinase; JAK: Janus kinase;
STAT: signal transducer and activator of transcription; IFN-γ: interferon-γ; IL: interleukin; FEV0.3: forced expiratory flow in 0.3 s; FVC:
forced vital capacity; PEF: peak expiratory flow. a, b is the P value range, between the abscissa and ordinate index, aP < 0.05, bP < 0.01.
M 1 2 3 4 5bp
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1000
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Figure 4 Expression of JAK1/STAT3 signaling pathway, and
MMP-9, TIMP1 mRNA in each group
M: marker; 1: NC group; 2: MC group; 3: LWBQ group; 4: JSB
group; 5: PAT group. The normal and model groups were giv-
en normal saline (0.09 g/kg); Liuweibuqi group was given Li-
uweibuqi capsule (0.35 g/kg); Jinshuibao group was given
Jinshuibao capsules (0.495 g/kg), and the Spleen group was
given spleen aminopeptidase (0.33 mg/kg), once a day for
30 days. NC: normal control; MC: model control; LWBQ: Liu-
weibuqi capsule; JSB: Jinshuibao capsule; PAT: spleen amino-
peptidase; MMP: matrix metalloproteinase; TIMP: tissue in-
hibitor of matrix metalloproteinase; JAK: janus kinase; STAT:
signal transducer and activator of transcription.
1 2 3 4 5
JAK1
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STAT3
p-STAT3
MMP-9
TIMP1
β-actin
kDa
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Figure 5 Expression of JAK1/STAT3 signaling pathway, and
MMP-9, TIMP1 protein in each group
1: NC group; 2:MC group; 3: JBS group; 4: PAT group; 5: LW-
BQ group. The normal and model groups were given normal
saline (0.09 g/kg); Liuweibuqi group was given Liuweibuqi
capsule (0.35 g/kg); Jinshuibao group was given Jinshuibao
capsules (0.495 g/kg), and the Spleen group was given
spleen aminopeptidase (0.33 mg/kg), once a day for 30
days. NC: normal control; MC: model control; LWBQ: Liu-
weibuqi capsule; JSB: Jinshuibao capsule; PAT: spleen amino-
peptidase; MMP: matrix metalloproteinase; TIMP: tissue in-
hibitor of matrix metalloproteinase; JAK: janus kinase; STAT:
signal transducer and activator of transcription.
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correlated with TIMP1. MMP-9 expression and
MMP-9/TIMP-1 was higher in the model group com-
pared with the normal group, indicating that there was
airway inflammation in COPD. Excessive activation of
the JAK1/STAT3 signaling pathways can reduce the ex-
pression of TIMP-1, which cannot effectively inhibit
MMP-9 expression. MMP-9 over-expression degraded
the enhanced role of the extracellular matrix, and in-
creased airway inflammation. Study showed that the
MMP/JAK/STAT3 signaling axis led to excessive acti-
vation of COX-2 expression, which causes airway and
lung tissue damage.12
Lung deficiency is the primary factor of COPD, and is
treated in TCM with supplementary Qi. This study
showed that Liuweibuqi capsules significantly im-
proved the signs and symptoms of COPD, improved
tissue morphology and lung function, increased IL-4,
IL-10, and TIMP1 expression, reduced JAK1, STAT3,
p-STAT3, and MMP-9 expression, and inflammation
in rats modeled with lung deficiency. Liuweibuqi cap-
sules include Renshen (Radix Ginseng), Huangqi (Ra-
dix Astragali Mongolici), Yuzhu (Rhizoma Polygonati od-
orati), Yizhi (Fructus Alpiniae Oxyphyllae), Chenpi
(Pericarpium Citri Reticulatae), Rougui (Cortex Cinna-
momi Cassiae). Renshen (Radix Ginseng) and Huangqi
(Radix Astragali Mongolici) may nourish vitality, accord-
ing to TCM. Ginseng polysaccharides and ginseng sa-
ponins can regulate immune function and reduce in-
flammation caused by LPS.13,14 Study found that astrag-
alus polysaccharides can not only reduce the body's in-
flammatory response, but also adjust the lung Qi role
of immunity in mice.15,16 Animal studies found that as-
tragalus has beneficial effects on allergic airway inflam-
mation inhibition.17 Moreover, Huangqi (Radix Astraga-
li Mongolici) can regulate the JAK/STAT pathway ex-
pression, and astragalus saponins can reduce JAK,
STAT1, and STAT3 protein expression. Astragalus
polysaccharides and saponins can inhibit MMP-9 and
TIMP-1 expression in damaged lung tissue and im-
prove lung function. Further study has found that
shenqi combination can reduce MMP-9 protein expres-
sion in rat lungs with COPD lung deficiency and in-
hibits extracellular matrix collagen deposition, which
prevents COPD airway remodeling.18 Citrus essential
oil can relax the tracheal smooth muscle. Moreover, cit-
rus has effects on asthma, and can promote humoral
and cellular immunity.19 Finally, cinnamon water ex-
tract can inhibit NO production, has anti-inflammato-
ry effects, and can inhibit reticuloendothelial phagocy-
tosis and antibody formation, thereby regulating the
body's immune function.20
In summary, Liuweibuqi capsules improved COPD
symptoms. The mechanism behind it is possibly relat-
ed to the regulation of JAK1/STAT3 signal transduc-
tion, the balance of MMP-9/TIMP-1, and inhibition
of the inflammatory response.
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